<DOC>
	<DOC>NCT02900157</DOC>
	<brief_summary>This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male and female subjects 18 years and older Must have histologic documentation of advanced solid tumors Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option Concurrent enrollment in another clinical study Prior participation in clinical studies that include durvalumab alone or in combination Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>MEDI9090</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
</DOC>